Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice

References

• Watson WJ, Seiden HS. Alzheimer’s disease: a current review. Can. Fam. Physician. 1984;30:595–599.
   PubMed Web of Science ®Google Scholar
• Gomez-Ramirez J, Wu J. Network-based biomarkers in Alzheimer’s disease: review and future directions. Front. Aging Neurosci. 2014;6:12.
   PubMed Web of Science ®Google Scholar
• Takashima A, Noguchi K, Sato K, et al. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. USA. 1993;90:7789–7793.10.1073/pnas.90.16.7789
   PubMed Web of Science ®Google Scholar
• Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 1999;66:137–147.10.1136/jnnp.66.2.137
   PubMed Web of Science ®Google Scholar
• Kar S, Slowikowski SP, Westaway D, et al. Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J. Psychiatry Neurosci. 2004;29:427–441.
   PubMed Web of Science ®Google Scholar
• Gil-Bea FJ, García-Alloza M, Domínguez J, et al. Evaluation of cholinergic markers in Alzheimer’s disease and in a model of cholinergic deficit. Neurosci. Lett. 2005;375:37–41.10.1016/j.neulet.2004.10.062
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Yamanish Y, Iimura Y, et al. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr. Med. Chem. 2000;7:303–339.10.2174/0929867003375191
   PubMed Web of Science ®Google Scholar
• Lilienfeld S. Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002;8:159–176.
   PubMedGoogle Scholar
• Anagnostaras SG, Maren S, Fanselow MS. Scopolamine selectively disrupts the acquisition of contextual fear conditioning in rats. Neurobiol. Learn. Mem. 1995;64:191–194.10.1006/nlme.1995.0001
   PubMed Web of Science ®Google Scholar
• Yang JH, Han SJ, Ryu JH, et al. Ginsenoside Rh2 ameliorates scopolamine-induced learning deficit in mice. Biol. Pharm. Bull. 2009;32:1710–1715.10.1248/bpb.32.1710
   PubMed Web of Science ®Google Scholar
• Uchida S, Endo S, Akita K, et al. The cyanine dye NK-4 improves scopolamine-induced memory impairments in mice. Biol. Pharm. Bull. 2012;35:1831–1835.10.1248/bpb.b12-00370
   PubMed Web of Science ®Google Scholar
• Guo B, Xu L, Wei Y, et al. [Research advances of Huperzia serrata (Thunb.) Trev]. Zhongguo Zhong Yao Za Zhi. 2009;34:2018–2023.
   PubMedGoogle Scholar
• Zhang HY, Zheng CY, Yan H, et al. Potential therapeutic targets of huperzine A for Alzheimer’s disease and vascular dementia. Chem. Biol. Interact. 2008;175:396–402.10.1016/j.cbi.2008.04.049
   PubMed Web of Science ®Google Scholar
• Ma X, Tan C, Zhu D, et al. Huperzine A from Huperzia species—an ethnopharmacolgical review. J. Ethnopharmacol. 2007;113:15–34.10.1016/j.jep.2007.05.030
   PubMed Web of Science ®Google Scholar
• Suh WH, Suslick KS, Suh YH. Therapeutic agents for Alzheimer’s disease. Curr. Med. Chem. 2005;5:259–269.
   Google Scholar
• Tang XC, Han YF. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev. 1999;5:281–300.
   Google Scholar
• Ye JW, Cai JX, Wang LM, et al. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J. Pharmacol. Exp. Ther. 1999;288:814–819.
   PubMed Web of Science ®Google Scholar
• Szypuła WJ, Kiss AK, Pietrosiuk A, et al. Determination of huperzine a in Huperzia selago plants from wild population and obtained in in vitro culture by high-performance liquid chromatography using a chaotropic mobile phase. Acta Chromatographica. 2011;23:339–352.10.1556/AChrom.23.2011.2.11
   Web of Science ®Google Scholar
• Ferreira A, Rodrigues M, Fortuna A, et al. Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology. Phytochem. Rev. 2014. DOI 10.1007/s11101-014-9384-y.
   Google Scholar
• Bai DL, Tang XC, He XC. Huperzine A, a potential therapeutic agent for treatment of Alzheimer’s disease. Curr. Med. Chem. 2000;7:355–374.10.2174/0929867003375281
   PubMed Web of Science ®Google Scholar
• Kasa P, Papp H, Kasa P Jr, et al. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience. 2000;101:89–100.10.1016/S0306-4522(00)00335-3
   PubMed Web of Science ®Google Scholar
• Saxena A, Qian N, Kovach IM, et al. Identification of amino acid residues involved in the binding of huperzine A to cholinesterases. Protein Sci. 1994;3:1770–1778.10.1002/pro.v3:10
   PubMed Web of Science ®Google Scholar
• Mandillo S, Tucci V, Hölter SM, et al. Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study. Physiol. Genomics. 2008;34:243–255.10.1152/physiolgenomics.90207.2008
   PubMed Web of Science ®Google Scholar
• Kumar H, Kim BW, Song SY, et al. Cognitive enhancing effects of alpha asarone in amnesic mice by influencing cholinergic and antioxidant defense mechanisms. Biosci. Biotechnol. Biochem. 2012;76:1518–1522.10.1271/bbb.120247
   PubMed Web of Science ®Google Scholar
• Oike Y, Hata A, Mamiya T, et al. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum. Mol. Genet. 1999;8:387–396.10.1093/hmg/8.3.387
   PubMed Web of Science ®Google Scholar
• Zhu XD, Giacobini E. Second generation cholinesterase inhibitors: Effect of (L)-huperzine-A on cortical biogenic amines. J. Neurosci. Res. 1995;41:828–835.10.1002/(ISSN)1097-4547
   PubMed Web of Science ®Google Scholar
• Gordon RK, Nigam SV, Weitz JA, et al. The NMDA receptor ion channel: a site for binding of huperzine A. J. Appl. Toxicol. 2001;21:S47–S51.10.1002/(ISSN)1099-1263
   Google Scholar
• Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin. 2006;27:1–26.10.1111/aphs.2006.27.issue-1
   PubMed Web of Science ®Google Scholar
• Shannon HE, Peters SC. A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. J. Pharmacol. Exp. Ther. 1990;255:549–553.
   PubMed Web of Science ®Google Scholar
• Ukai M, Kobayashi T, Kameyama T. Characterization of the effects of scopolamine on the habituation of exploratory activity: differential effects of oxotremorine and physostigmine. Gen. Pharmacol. 1994;25:433–438.10.1016/0306-3623(94)90193-7
   PubMedGoogle Scholar
• Hornick A, Schwaiger S, Rollinger JM, et al. Extracts and constituents of Leontopodium alpinum enhance cholinergic transmission: Brain ACh increasing and memory improving properties. Biochem. Pharmacol. 2008;76:236–248.10.1016/j.bcp.2008.04.015
   PubMed Web of Science ®Google Scholar